Clinical trials: Drug Eluting Stents
Coronary Artery Disease (CAD), Ischemic Heart Disease
Coroflex® ISAR NEO PMCF Study
International, Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Coroflex® ISAR NEO coronary stent system to meet EU Medical Device…
- Trial name
- rEPIC07 (NCT05698732)
- Testing
- Coroflex® ISAR NEO coronary stent system
- Where
- 26 sites in France, Spain and 1 more
- Volunteers
- 3,000 people
- Sponsor
- Fundación EPIC
Coronary Artery Disease, Percutaneous Coronary Intervention
Study on the Preferences for PCI Implantation Devices Among Doctors and Patients
The contemporary percutaneous treatment of coronary artery disease typically involves initial lesion preparation with balloon angioplasty, followed by the deployment of a drug-eluting stent (DES) to provide an immediate scaffold…
- Trial name
- REC-DEVICEPREF (NCT07378163)
- Testing
- Questionnaire
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Xijing Hospital
Coronary Disease
Reduced Anti-Platelet Therapy With Pimecrolimus Drug Eluting Stent (RAPID)
Non-randomized, single arm, multi-center, clinical trial evaluating the Corio™ pimecrolimus-eluting stent with reduced anti-platelet therapy in patients with de novo lesions of the native coronary arteries.
- Trial name
- NCT00322543
- Testing
- Corio™ Pimecrolimus-eluting stent
- Where
- Brazil
- Volunteers
- 3 people
- Sponsor
- Conor Medsystems
Atrial Fibrillation
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents
Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy…
- Trial name
- NCT04250116
- Testing
- NOAC monotherapy, Dual antithrombotic therapy with NOAC and clopidogrel
- Where
- South Korea
- Volunteers
- 960 people
- Sponsor
- Yonsei University
Chronic Total Occlusion of Coronary Artery
To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.
This study aims to evaluate the treatment of Chronic total occlusion (CTO) disease. Whether Intravascular Ultrasonography (IVUS) guiding the implantation of drug-eluting stents (DES) will provide better long-term clinical…
- Trial name
- CRUISE-CTO (NCT04944615)
- Testing
- The guidewire successfully passed the CTO lesion
- Where
- China
- Volunteers
- 1,448 people
- Sponsor
- CCRF Inc., Beijing, China
Coronary Artery Disease
The DECISION-CTO Extended 10 Y Follow-up
The goal of this study is to compare the 10-year clinical outcomes of an initial strategy of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO-PCI) with an initial strategy of no CTO-PCI in patients with…
- Trial name
- DecisionCTO10Y (NCT06908499)
- Where
- 19 sites in India, Indonesia and 3 more
- Volunteers
- 804 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Peripheral Arterial Disease
Zilver® PTX® V Clinical Study
The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of…
- Trial name
- NCT01901289
- Testing
- Zilver® PTX® Drug-Eluting Peripheral Stent
- Where
- 17 sites in United States
- Volunteers
- 200 people
- Sponsor
- Cook Research Incorporated
Coronary Artery Disease
Everolimus-eluting(PROMUS-ELEMENT) vs. Biolimus A9-Eluting(NOBORI) Stents for Long-Coronary Lesions
This randomized study is a multi-center, randomized, study to compare the efficacy of biolimus A9-eluting stent (Nobori) vs. everolimus-eluting stent (Promus Element) for long coronary lesions.
- Trial name
- LONG-DES-V (NCT01186120)
- Testing
- Biolimus A9-eluting stent, Everolimus-eluting stent
- Where
- 11 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Seung-Jung Park
Coronary Heart Disease, Drug Eluting Stent
Study on Absorbable Zinc Alloy Drug Eluting Coronary Stent System
This trial is a prospective, two center single group registration pilot trial aiming to evaluate the product safety, and provide information for the later confirmatory test design according to the results.
- Trial name
- NCT05477940
- Testing
- Absorbable zinc alloy drug eluting coronary stent system
- Volunteers
- 30 people
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
Coronary Disease, Coronary Artery Disease
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT II (NCT00180310)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease (CAD), Stenosis Coronary
Brazilian Prospective Registry of the Inspiron EVO Drug-Eluting Stent in Complex Coronary Lesions
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population.
- Conditions
- Coronary Artery Disease (CAD), Stenosis Coronary, Small Vessel Ischemic Disease, Multivessel Coronary Artery Disease
- Trial name
- PCI EVOlution (NCT07491107)
- Testing
- Inspiron EVO Drug-Eluting Stent
- Where
- Brazil
- Volunteers
- 2,000 people
- Sponsor
- Scitech Produtos Medicos SA
Coronary Artery Disease
Optical Coherence Tomography for Drug Eluting Stent Safety
Increasing lesion complexity in percutaneous coronary interventions (PCI) has warranted the use of overlapping drug-eluting stents.
- Trial name
- ODESSA (NCT00693030)
- Testing
- sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co), paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS), zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Coronary Artery Disease, Myocardial Infarction
Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation
Coronary artery disease is one of the most prevalent diseases in the western countries. A waxy substance called plaque can build up inside the coronary arteries.
- Trial name
- OCTACS (NCT02272283)
- Testing
- Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation
- Volunteers
- 100 people
- Sponsor
- Odense University Hospital
Diabetes Mellitus Type II, Acute Coronary Syndrome
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
The purpose of this study is to determine if, in type 2 diabetic patients undergoing treatment with PCI and a stent, who fail to respond to normal doses of clopidogrel, a loading dose of 60 mg of prasugrel followed by 10 mg once…
- Trial name
- VERDI (NCT01684813)
- Testing
- Prasugrel., Clopidogrel
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Coronary Disease
Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution in Native Coronary Artery Lesions
The primary objective of this study is to evaluate the target lesion failure rate of the NEVO Sirolimus-eluting Coronary Stent System.
- Trial name
- NEVO RES-II (NCT00714883)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System
- Where
- 2 sites in Germany, Latvia
- Volunteers
- 3 people
- Sponsor
- Cordis US Corp.
Acute ST Segment Elevation Myocardial Infarction
Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study
The aim of the study is to demonstrate the safety and efficacy of the TCD-10023 (Ultimaster) sirolimus eluting stent in patients with acute ST-elevation myocardial infarction (STEMI), by proving superiority with respect to…
- Trial name
- MASTER (NCT02828683)
- Testing
- PCI in patients with ST-elevation myocardial infarction
- Where
- 13 sites in Brazil, Italy and 3 more
- Volunteers
- 500 people
- Sponsor
- Terumo Europe N.V.
Coronary Artery Disease
A First-in-Man Study of the Firesorb BVS (FUTURE-I)
This study is a small scale pilot trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) in Patients with Coronary Artery Disease for the first time.
- Trial name
- FUTURE-I (NCT02659254)
- Testing
- Sirolimus Target Eluting Bioresorbable Vascular Scaffold
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Atherosclerosis of Native Arteries of the Extremities
Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
- Trial name
- MAJESTIC (NCT01820637)
- Testing
- The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
- Where
- 13 sites in Australia, Austria and 3 more
- Volunteers
- 57 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial
The main objective of this study is to assess the safety and effectiveness of the Sirolimus-eluting stent CYPHERTM and/or updated version in reducing angiographic in-stent late loss in de novo native coronary lesions of diabetic…
- Trial name
- DESSERT (NCT00497172)
- Testing
- CYPHER Sirolimus-eluting stent, Bx SONIC bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.